A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activityWOOD, Edgar; CROSBY, Renae M; PEEL, Michael R et al.Anti-cancer drug design. 2001, Vol 16, Num 1, pp 1-6, issn 0266-9536Article

Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitorsVASSILEV, Lyubomir T; KAZMER, Sonja; MARKS, Ian M et al.Anti-cancer drug design. 2001, Vol 16, Num 1, pp 7-17, issn 0266-9536Article

Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationshipsWOOD, Lynn; LEESE, Matthew P; LEBLOND, Bertrand et al.Anti-cancer drug design. 2001, Vol 16, Num 4-5, pp 209-215, issn 0266-9536Article

Investigations on the biological properties of the lipophilic DHFR-inhibitory benzoprims reveal non-folate modes of action and opportunities for anti-cancer drug designCROUGHTON, Karen A; MATTHEWS, Charles S; GRIFFIN, Roger J et al.Anti-cancer drug design. 2001, Vol 16, Num 2-3, pp 119-128, issn 0266-9536Article

Spin-labeled 1-alkyl-1-nitrosourea synergists of antitumor antibioticsGADJEVA, Vesselina; KOLDAMOVA, Radosveta.Anti-cancer drug design. 2001, Vol 16, Num 4-5, pp 247-253, issn 0266-9536Article

Synthesis, cytotoxicity, cell uptake and DNA interstrand cross-linking of 4,4'-dipyrazolylmethane-linked multinuclear platinum anti-cancer complexesWHEATE, Nial J; CULLINANE, Carleen; WEBSTER, Lorraine K et al.Anti-cancer drug design. 2001, Vol 16, Num 2-3, pp 91-98, issn 0266-9536Article

The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variablesDODDS, Helen M; HANRAHAN, Jane; RIVORY, Laurent P et al.Anti-cancer drug design. 2001, Vol 16, Num 4-5, pp 239-246, issn 0266-9536Article

The interaction of DNA-targeted platinum phenanthridinium complexes with DNA in human cellsWHITTAKER, Joanne; MCFADYEN, W. David; BAGULEY, Bruce C et al.Anti-cancer drug design. 2001, Vol 16, Num 2-3, pp 81-89, issn 0266-9536Article

The role of ring D in the antitumour antibiotic streptonigrin: metal complexation, DNA binding and topoisomerase inhibition by ABC ring analogues of streptonigrinANDERBERG, Pia I; HARDING, Margaret M.Anti-cancer drug design. 2001, Vol 16, Num 2-3, pp 143-153, issn 0266-9536Article

Adriamycin-induced inhibition of mitochondrial-encoded polypeptides as a model system for the identification of hotspots for DNA-damaging agentsSHARPLES, Robyn A; CULLINANE, Carleen; PHILLIPS, Don R et al.Anti-cancer drug design. 2000, Vol 15, Num 3, pp 183-190, issn 0266-9536Article

Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugsPETTIT, George R; LIPPERT, John W.Anti-cancer drug design. 2000, Vol 15, Num 3, pp 203-216, issn 0266-9536Article

Design of two etoposide-amsacrine conjugates : topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicityARIMONDO, Paola; BOUKARIM, Chawki; BAILLY, Christian et al.Anti-cancer drug design. 2000, Vol 15, Num 6, pp 413-421, issn 0266-9536Article

Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo[2,1-c] [1,4]benzodiazepine (PBD)-polyamide conjugates and 2,2'-PBD dimersPRAVEEN REDDY, B. S; DAMAYANTHI, Yalamati; NARAYAN REDDY, B. S et al.Anti-cancer drug design. 2000, Vol 15, Num 3, pp 225-238, issn 0266-9536Article

Imidazo[2,1-b]thiazolylmethylene- and indolylmethylene-2-indolinones : A new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibitionANDREANI, Aldo; CAVALLI, Andrea; GRANAIOLA, Massimiliano et al.Anti-cancer drug design. 2000, Vol 15, Num 6, pp 447-452, issn 0266-9536Article

Naturally occurring and synthetic inhibitors of NF-κB functionsUMEZAWA, Kazuo; ARIGA, Akiko; MATSUMOTO, Naoki et al.Anti-cancer drug design. 2000, Vol 15, Num 4, pp 239-244, issn 0266-9536Article

Synthesis and antimelanoma activity of analogues of N-acetyl-4-S-cysteaminylphenolLANT, Neil J; MCKEOWN, Paul; KELLAND, Lloyd R et al.Anti-cancer drug design. 2000, Vol 15, Num 4, pp 295-302, issn 0266-9536Article

Synthesis of tetracyclic benzodioxins as potential antitumour agentsSPICER, Julie A; DENNY, William A.Anti-cancer drug design. 2000, Vol 15, Num 6, pp 453-458, issn 0266-9536Article

Tetramethylpiperidine-substitution increases the antitumor activity of the riminophenazines for an acquired multidrug-resistant cell lineVAN RENSBURG, C. E. J; JOONE, G. K; O'SULLIVAN, J. F et al.Anti-cancer drug design. 2000, Vol 15, Num 4, pp 303-306, issn 0266-9536Article

The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma spheroidsGEDDA, Lars; GHANEOLHOSSEINI, Hadi; NILSSON, Per et al.Anti-cancer drug design. 2000, Vol 15, Num 4, pp 277-286, issn 0266-9536Article

Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structureKESKIN, O; BAHAR, I; JERNIGAN, R. L et al.Anti-cancer drug design. 2000, Vol 15, Num 2, pp 79-98, issn 0266-9536Article

In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell linesJOHNSTONE, S. A; GELMON, K; MAYER, L. D et al.Anti-cancer drug design. 2000, Vol 15, Num 2, pp 151-160, issn 0266-9536Article

The quinobenzoxazines : relationship between DNA binding and biological activityYAN KWOK; DAEKYU SUN; CLEMENT, J. J et al.Anti-cancer drug design. 1999, Vol 14, Num 5, pp 443-450, issn 0266-9536Article

5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) : DNA binding and patterns of cytotoxicitySPICER, J. A; FINLAY, G. J; BAGULEY, B. C et al.Anti-cancer drug design. 1999, Vol 14, Num 1, pp 37-45, issn 0266-9536Article

Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds : use of a PCR method for the facile preparation of single end-labelled double-stranded DNAGIESEG, M. A; MATEJOVIC, J; DENNY, W. A et al.Anti-cancer drug design. 1999, Vol 14, Num 1, pp 77-84, issn 0266-9536Article

Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNABONFANTI, M; LA VALLE, E; FERNANDEZ SOUSA FARO, J.-M et al.Anti-cancer drug design. 1999, Vol 14, Num 3, pp 179-186, issn 0266-9536Article